ImpediMed Ltd
ASX:IPD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
ImpediMed Ltd
ASX:IPD
|
AU |
|
TYMLEZ Group Ltd
ASX:TYM
|
AU |
|
Freshworks Inc
NASDAQ:FRSH
|
US |
|
Archer-Daniels-Midland Co
NYSE:ADM
|
US |
|
HITO-Communications Holdings Inc
TSE:4433
|
JP |
|
I
|
Ishii Iron Works Co Ltd
TSE:6362
|
JP |
|
Axis Bank Ltd
NSE:AXISBANK
|
IN |
|
First Western Financial Inc
NASDAQ:MYFW
|
US |
|
A
|
Applied Nutrition PLC
LSE:APN
|
UK |
|
A
|
Adidas AG
OTC:ADDDF
|
DE |
ImpediMed Ltd
ImpediMed Ltd is a medical technology company that makes devices and software for measuring body fluid and tissue composition with bioimpedance spectroscopy. Its best-known product is the SOZO system, which gives clinicians a quick, non-invasive read on fluid changes in patients. The company focuses on turning those measurements into practical tools for early detection and ongoing monitoring, especially in cancer care and heart failure care. The main customers are hospitals, oncology centers, cardiology practices, and other clinics that monitor patients at risk of fluid-related complications such as lymphedema. ImpediMed sells its systems to healthcare providers and also earns recurring income from software, data, and usage-based services tied to the platform. In simple terms, it makes money by placing its measurement tools into clinical workflows and then charging for the hardware and the ongoing access around it. What makes ImpediMed different is that it sits at the point where imaging, monitoring, and digital records meet. Instead of being a general medical equipment maker, it focuses on one specific measurement method that can help clinicians spot changes earlier than a physical exam alone. That gives it a niche role in care pathways where repeated, standardized measurements matter more than one-time testing.
ImpediMed Ltd is a medical technology company that makes devices and software for measuring body fluid and tissue composition with bioimpedance spectroscopy. Its best-known product is the SOZO system, which gives clinicians a quick, non-invasive read on fluid changes in patients. The company focuses on turning those measurements into practical tools for early detection and ongoing monitoring, especially in cancer care and heart failure care.
The main customers are hospitals, oncology centers, cardiology practices, and other clinics that monitor patients at risk of fluid-related complications such as lymphedema. ImpediMed sells its systems to healthcare providers and also earns recurring income from software, data, and usage-based services tied to the platform. In simple terms, it makes money by placing its measurement tools into clinical workflows and then charging for the hardware and the ongoing access around it.
What makes ImpediMed different is that it sits at the point where imaging, monitoring, and digital records meet. Instead of being a general medical equipment maker, it focuses on one specific measurement method that can help clinicians spot changes earlier than a physical exam alone. That gives it a niche role in care pathways where repeated, standardized measurements matter more than one-time testing.
Record Revenue: Quarterly revenue reached a record $3.9 million, up 18% year-on-year and 8% on the prior quarter.
Cash Flow Improvement: Operating cash outflow dropped significantly to $2.9 million from $5.6 million last quarter, extending the company's cash runway.
Strong Reimbursement Gains: U.S. reimbursement coverage for SOZO in breast cancer-related lymphedema reached 93%, covering 323 million lives and up 5% from last quarter.
Mixed Sales Performance: Rest of world sales were strong, but U.S. sales for breast cancer-related lymphedema were softer than expected due to hospital budget constraints.
Growth Pipeline: Over 700 sales opportunities are in the pipeline, with confidence expressed in future growth as conditions stabilize.
Strategic Progress: FDA clearance was received for a new bilateral lymphedema algorithm, and a new 510(k) was filed for an expanded body composition offering.
Expansion in New Segments: Launch and positive feedback for SOZO Pro in heart health, wellness, and weight management markets, with first heart health sales in progress.
